Xenon Pharmaceuticals XENE Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's operating lease right-of-use assets in other assets?
- Xenon Pharmaceuticals (XENE) reported operating lease right-of-use assets in other assets of $6.29M in Q1 2026.
- How has Xenon Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Xenon Pharmaceuticals's operating lease right-of-use assets in other assets decreased by 17.4% year-over-year, from $7.62M to $6.29M.
- What is the long-term trend for Xenon Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a 14.8% compound annual growth rate (CAGR), from $3.33M to $6.63M.